**Supplementary Table e-2: Patients with post-HSE autoimmune encephalitis according to age and antibody findings**

|  |  |  |
| --- | --- | --- |
|  | **Adult-teenagers =8** | **Young Children =6** |
| **Male (%)** | 5 (63%) | 3 (50%) |
| **Age,** median (range) | 40 years (13-69) | 13 months (6-20) |
| **Residual deficits post viral infection**  **Mild (mRS ≤2)**  **Severe (mRS >2)** | 4 (50%)  4 (50%) | 5 (83%)  1 (17%) |
| **Median time from HSE to relapsing symptoms (range)** | 39 days (12-51) | 27 days (17-40) |
| **Symptoms at relapse**   * Seizures * Choreoathetosis * Irritability * Abnormal behavior * Autonomic instability * Decreased level of consciousness | 1 (13%)  0\*  6 (75%)  7 (88%)  1 (13%)  2 (25%)\* | 3 (50%)  6(100%)\*  6 (100%)  Not assessable  Not reported  6 (100%)\* |
| **Ancillary tests at relapse**   * Pleocytosis * Increased CSF proteins * Contrast enhancing brain MRI | 5 (63%)  4 (50%)  5/6 (83%) (n/a in 2) | 5/5 (100%) (n/a in 1)  3/5 (60%) (n/a in 1)  1/3 (33%) (n/a in 3) |
| **Median time from relapse to antibody testing (range)** | 87 days (17-296)\*\* | 4 days (0-55)\*\* |
| **Median time from relapse to immunotherapy (range)** | 79 days (17-352)\*. one not treated | 4 days (0-12)\* |
| **Antibody Findings** | 5 NMDAR (62.5%);  3 unknown antigens | 6 NMDAR (100%)  (one concurrent GABAAR) |
| **Immunotherapy**   * Steroids * IVIg * Plasma exchange * Rituximab alone * Rituximab combined with cyclophosphamide | 7 (88%)  3 (38%)  1 (13%)  1 (13%)  1 (13%) | 4 (67%)  4 (67%)  3 (50%)  3 (50%)  1 (17%) |
| **Follow up >1mo,**  **median (range)** | 8 patients  12 months ( 2-20) | 5 patients  5 months (4-12) |
| **Improvement of relapsing symptoms (return to base line deficits post-HSE)** | Complete 7 (87%)  Partial 1 (13%)  No improvement 0 | Complete 0  Partial 3 (60%)  No improvement 2 (40%) |

Table e-2 Legend: \* p< 0,01; \*\* p=0,037; \*\*\* p=0,043. Abbreviations: CSF: cerebrospinal fluid, GABAAR: gamma amino butyric acid A receptor, HSE: herpes simplex virus encephalitis, IVIg: intravenous immunoglobulins, mo: months, mRS: modified Rankin Score, NMDAR: N-methyl-D-aspartate receptor